The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It's yet another Buy rating from Investors Chronicle
https://www.investorschronicle.co.uk/news/2023/10/26/the-aim-100-2023-10-to-1/
No budget, apart from the £168 Billion that we, the taxpayer has given them this year
What are you doing 1pencil? are you buying?
Haha well I am buying again at the moment ;o-)
Sorry Amones, yes it was, apologies for the lack of context
I thought it was interesting given AZ's tie-up with HCM. Not directly related of course but I thouigh the background iswas interesting and relevant
AstraZeneca has said that an anti-corruption investigation launched by China in the healthcare sector has hit prescription volumes and access to doctors.
The FTSE 100 pharmaceuticals company, which is the biggest multinational drug group operating in the world’s second-largest economy, issued the warning in an “aide memoire” before its third-quarter trading update next month.
President Xi’s administration intensified a clampdown on bribery, embezzlement and fraud across the country’s healthcare sector in August. Hospital bosses and chief executives of local drug companies have been detained, pharma company access to hospitals has been curtailed, share prices have been hit and initial public offerings have been pulled.
Beijing’s campaign has created further uncertainty for overseas drug companies active in the country. AstraZeneca has grown quickly in China over the past decade, with the country accounting for 13 per cent of its $44.3 billion total group sales last year, up from 5 per cent a decade ago.
Underlining the growing importance of China to AstraZeneca’s future, Leon Wang, who heads its China operations, vowed in May that it would be a patriotic company that “loves the Communist Party and loves the country” during celebrations to mark the 30th anniversary of AstraZeneca in China.
In the note to investors and analysts AstraZeneca said it anticipated that the corruption investigation would “benefit compliant companies in the longer term” but said “the company has seen a reduction in access to physicians as well as some negative impact on prescription volumes. These investigations were not anticipated at the time of first-half results [in July].”
Analysts at Stifel told clients that the expectation had been for a return to growth in China this year for AstraZeneca, adding: “The statement underpins possible unexpected consequences on the business impacting the end of the third quarter and possibly fourth quarter.”
I'd like to think that Hutchmed would work to in-license other firms drugs into China to leverage their extensive coverage and sales network. They need to continue to think more flexibly and be dynamic in their path towards becoming profitable as soon as they can. Interesting price movement on NASDAQ today - it was up over 10% a short time ago........
Happy to hear this too "The FDA review is progressing and the inspection of HUTCHMED’s manufacturing facility in Suzhou, China has been completed"
We are still way under valued on all metrics including DCF compared to Beigene and Innovent, something that must surely correct itself at some point
a thorny subject jatw - i was in hk the day fru*****inib was approved, which as you will recall was hutchmed's first every approved drug - the share price went down quite significantly, so i am not sure what the market will do.
that said, the first ever global approval should be more significant, even though it's now out licensed to takeda
325p sounds fair, and maybe we will get quite of lot of short covering to help
Trinity Delta also published a new detailed research note on Thursday
https://www.trinitydelta.org/wp-content/uploads/2023/09/HCM-Outlook-230907.pdf
As the majority shareholder I wonder what CKHH would want in order to be tempted 1 pencil?
The Company has just posted a new Corporate Presentation with various updated content including Savo BTD
https://www.hutch-med.com/wp-content/uploads/2023/09/pre230906.pdf
Nod nod nod nod!!
China has significantly cut stamp duty on share trading in a bid to boost market activity
Small volume, volatile, but at least it's not down today
Does anyone have any estimate (guess) about what the share price will be in 5 years time, just curious if people have any faith in DCF models....??
As was commented on recently, very very low volumes being traded these days, 35 mins in and 1500 shares traded
Gina Raimondo is heading to China next week with an olive branch - hopefully there will be some positives to come out of her meetings
Various commentary on Bloomberg TV & Radio over the past few days about U.S. Funds winding down their positions in Chinese equities - a trend that is set to continue according to various Equity Analysts and commentators
I agree 1pencil, and a very clear path now to profitability. Clearly the market ignores the DCF calculations these days and want to see hard cash and Free Cashflow, nothing less will do. Let's hope the Nov 30th PDUFA bears fruit otherwise we will no doubt get hammered again!